Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | XBP1 | P17861 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25642144 | 0.91 | PIN1 (0.55) | ALDH1A1HTTXBP1RAB9APIN1 | |
| SCHEMBL30074646 | 0.91 | PIN1 (0.55) | ALDH1A1HTTXBP1RAB9APIN1 | |
| SCHEMBL31613080 | 0.85 | ALDH1A1 (0.52) | ALDH1A1HTTXBP1RAB9APIN1 | |
| SCHEMBL9522314 | 0.81 | C5AR1 (0.46) | KMT2AMEN1 | |
| SCHEMBL10468632 | 0.79 | ALDH1A1 (0.45) | ALDH1A1HTTXBP1RAB9APIN1 | |
| SCHEMBL17615821 | 0.79 | ALDH1A1 (0.51) | ALDH1A1HTTXBP1PIN1KMT2A | |
| SCHEMBL769134 | 0.79 | KMT2A (0.51) | ALDH1A1HTTPIN1KMT2AMEN1 | |
| SCHEMBL29484101 | 0.79 | KMT2A (0.51) | ALDH1A1HTTPIN1KMT2AMEN1 | |
| SCHEMBL10469822 | 0.79 | ALDH1A1 (0.50) | ALDH1A1HTTXBP1RAB9APTGDR2 | |
| SCHEMBL31262315 | 0.77 | HTT (0.49) | ALDH1A1HTTXBP1RAB9APIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111936471-B | Non-fused thiophene derivatives and uses thereof | 埃尼奥制药公司 | 2024-10-29 | — | — | CN | disclosed |
| US-11767316-B2 | Non-fused thiophene derivatives and their uses | ENYO PHARMA (FR) | 2023-09-26 | — | — | US | disclosed |
| US-20210040059-A1 | NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES | Institut National de la Santé et de la Recherche Médicale (FR) | 2021-02-11 | — | — | US | disclosed |
| CN-111936471-A | Non-fused thiophene derivative and use thereof | 埃尼奥制药公司 | 2020-11-13 | — | — | CN | disclosed |
| US-20120071506-A1 | METHODS FOR TREATING CNS DISORDERS WITH BICYCLO-SUBSTITUTED 2-IMIDAZOLINE AND 2-IMIDAZOLES | GALLEY GUIDO (DE) | 2012-03-22 | — | — | US | disclosed |
| US-20070197620-A1 | Methods for treating CNS disorders with bicyclo-substituted 2-imidazoline and 2-imidazoles | HOFFMANN-LA ROCHE INC. | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071506-A1 | METHODS FOR TREATING CNS DISORDERS WITH BICYCLO-SUBSTITUTED 2-IMIDAZOLINE AND 2-IMIDAZOLES | CRY1, PER2, GPR119 | ALDH1A1 1716/4885HTT 442/4885XBP1 1565/4885 |
| US-20210040059-A1 | NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES | FTH1, SLC40A1, FECH | ALDH1A1 1977/4885HTT 701/4885XBP1 839/4885 |
| US-11767316-B2 | Non-fused thiophene derivatives and their uses | FTH1, SLC40A1, FECH | ALDH1A1 1977/4885HTT 701/4885XBP1 839/4885 |
| US-20070197620-A1 | Methods for treating CNS disorders with bicyclo-substituted 2-imidazoline and 2-imidazoles | CRY1, PER2, GPR119 | ALDH1A1 1541/4885HTT 477/4885XBP1 1625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.